neuroreceptor imaging
Recently Published Documents


TOTAL DOCUMENTS

46
(FIVE YEARS 0)

H-INDEX

13
(FIVE YEARS 0)

NeuroImage ◽  
2020 ◽  
Vol 221 ◽  
pp. 117160
Author(s):  
Jörg Mauler ◽  
Alexander Heinzel ◽  
Andreas Matusch ◽  
Hans Herzog ◽  
Irene Neuner ◽  
...  


Author(s):  
Irene Graf ◽  
Matthäus Willeit ◽  
Siegfried Kasper ◽  
Nicole Praschak-Rieder


2017 ◽  
Vol 39 (5) ◽  
pp. 355-360 ◽  
Author(s):  
Denis Pavăl

Autism spectrum disorder (ASD) comprises a group of neurodevelopmental disorders characterized by social deficits and stereotyped behaviors. While several theories have emerged, the pathogenesis of ASD remains unknown. Although studies report dopamine signaling abnormalities in autistic patients, a coherent dopamine hypothesis which could link neurobiology to behavior in ASD is currently lacking. In this paper, we present such a hypothesis by proposing that autistic behavior arises from dysfunctions in the midbrain dopaminergic system. We hypothesize that a dysfunction of the mesocorticolimbic circuit leads to social deficits, while a dysfunction of the nigrostriatal circuit leads to stereotyped behaviors. Furthermore, we discuss 2 key predictions of our hypothesis, with emphasis on clinical and therapeutic aspects. First, we argue that dopaminergic dysfunctions in the same circuits should associate with autistic-like behavior in nonautistic subjects. Concerning this, we discuss the case of PANDAS (pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections) which displays behaviors similar to those of ASD, presumed to arise from dopaminergic dysfunctions. Second, we argue that providing dopamine modulators to autistic subjects should lead to a behavioral improvement. Regarding this, we present clinical studies of dopamine antagonists which seem to have improving effects on autistic behavior. Furthermore, we explore the means of testing our hypothesis by using neuroreceptor imaging, which could provide comprehensive evidence for dopamine signaling dysfunctions in autistic subjects. Lastly, we discuss the limitations of our hypothesis. Along these lines, we aim to provide a dopaminergic model of ASD which might lead to a better understanding of the ASD pathogenesis.



2016 ◽  
Vol 16 (16) ◽  
pp. 1830-1842 ◽  
Author(s):  
Alina Kassenbrock ◽  
Neil Vasdev ◽  
Steven H. Liang


2016 ◽  
pp. 31-48
Author(s):  
Greg Perlman ◽  
Christine DeLorenzo ◽  
J. John Mann ◽  
Ramin Parsey


RSC Advances ◽  
2016 ◽  
Vol 6 (9) ◽  
pp. 7288-7301 ◽  
Author(s):  
Puja Panwar Hazari ◽  
Surbhi Prakash ◽  
Virendra Kumar Meena ◽  
Niraj Singh ◽  
Krishna Chuttani ◽  
...  

An efficient approach in the design and synthesis of a multi-functional chelating agent based on 1-(2-methoxyphenyl)piperazine for targeting 5-HT1A receptors in brain was envisaged.



2016 ◽  
Vol 2016 ◽  
pp. 1-8 ◽  
Author(s):  
Ling Feng ◽  
Claus Svarer ◽  
Karine Madsen ◽  
Morten Ziebell ◽  
Agnete Dyssegaard ◽  
...  

This study aims at developing a simulation system that predicts the optimal study design for attaining tracer steady-state conditions in brain and blood rapidly. Tracer kinetics was determined from bolus studies and used to construct the system. Subsequently, the system was used to design inputs for bolus infusion (BI) or programmed infusion (PI) experiments. Steady-state quantitative measurements can be made with one short scan and venous blood samples. TheGABAAreceptor ligand [C11]Flumazenil (FMZ) was chosen for this purpose, as it lacks a suitable reference region.Methods. Five bolus [C11]FMZ-PET scans were conducted, based on which population-based PI and BI schemes were designed and tested in five additional healthy subjects. The design of a PI was assisted by an offline feedback controller.Results. The system could reproduce the measurements in blood and brain. With PI, [C11]FMZ steady state was attained within 40 min, which was 8 min earlier than the optimal BI (B/I ratio = 55 min).Conclusions. The system can design both BI and PI schemes to attain steady state rapidly. For example, subjects can be [C11]FMZ-PET scanned after 40 min of tracer infusion for 40 min with venous sampling and a straight-forward quantification. This simulation toolbox is available for other PET-tracers.



2014 ◽  
Vol 30 (5) ◽  
pp. 777-811 ◽  
Author(s):  
Peter Brust ◽  
Jörg van den Hoff ◽  
Jörg Steinbach


Author(s):  
Matthäus Willeit ◽  
Siegfried Kasper ◽  
Nicole Praschak-Rieder


2013 ◽  
Vol 52 ◽  
pp. 49-65 ◽  
Author(s):  
Jonathan B. Savitz ◽  
Wayne C. Drevets


Sign in / Sign up

Export Citation Format

Share Document